Stefano Del Prato, MD

Stefano Del Prato, MD PhD
 

Professor of Endocrinology and Metabolism
School of Medicine, University of Pisa
Chief of the Section of Diabetes
University of Pisa, Italy
Clinical Associate Professor of Medicine
University of Texas, San Antonio Health Science Center
San Antonio, Texas, USA


What advances in long-acting insulin and GLP-1 RA--and combination approaches--are having a positive impact on management of T2D? How should PK/PD properties affect our choice of specific GLP-1 RA?

What advances in long-acting insulin and GLP-1 RA--and combination approaches--are having a positive impact on management of T2D? How should PK/PD properties affect our choice of specific GLP-1 RA?

What are the ideal clinical profiles for and distinctions among the fixed ratio, combination formulations? What are their potential advantages and unique therapeutic windows of opportunities?

What are the ideal clinical profiles for and distinctions among the fixed ratio, combination formulations? What are their potential advantages and unique therapeutic windows of opportunities?

How will fixed ratio, basal insulin-GLP-1 RA combinations likely fit into the sequencing algorithm for diabetes care? How do we select among the available options? And in whom should we use these formulations?

How will fixed ratio, basal insulin-GLP-1 RA combinations likely fit into the sequencing algorithm for diabetes care? How do we select among the available options? And in whom should we use these formulations?